Kiniksa's Vixarelimab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis
Shots:
- The BTD is based on P-IIa assessing vixarelimab in reducing pruritus in patients with prurigo nodularis
- The study met its 1EPs i.e reduction in WI-NRS from baseline @8wks. in vixarelimab recipients and patients also received PN-IGA score of 0/1 @8wks.
- Kiniksa expects to initiate a P-IIb clinical trial of vixarelimab in prurigo nodularis- evaluating a range of once-monthly dose regimens- by the end of 2021. Vixarelimab is a fully-human mAb that targets oncostatin M receptor beta (OSMRβ)
Ref: GlobeNewswire | Image: Kiniksa
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com